This multicenter noninferiority design work included 1399 patients randomized to receive 6 months (n = 682) versus 1 year (n = 717) dual anti-aggregation after implantation of 2nd generation drug-eluting stent. The primary end point was a composite of cardiac death, myocardial infarction, stroke, definite or probable thrombosis, and major bleeding. At 12 months follow-up...

Previous studies suggest the excellent performance of the bioactive coated stent TITAN 2 compared with drug-eluting stents (DES). The aim of the study was to evaluate the results of this device in patients undergoing both ST segment elevation and without ST segment elevation acute coronary syndrome. A total of 1066 patients were included, of whom...

Spanish-Portuguese multicentre CIBELES study (Raul Moreno, Madrid, Spain) compared two drug-eluting stents – an everolimus (Xience V, Abbott Vascular, USA) and a sirolimus-releasing eluting stent (Cypher Select, Cordis Corporation, Miami Lakes, Florida, USA) in the context of total chronic coronary occlusions. With a non-inferiority design, the study randomized 208 patients (1:1), using as the primary...

Randomized prospective study comparing the everolimus-eluting polymer-coated stent versus a biodegradable polymer with biolimus coated stent.  While the use of first generation DES effectively reduces restenosis and reintervention rates, several meta-analyzes have shown a higher rate of late events of thrombotic origin associated with inflammatory phenomena and delayed reendothelialization at the site of implantation compared...

Fundamentals. Background: Although we’ve had more than a decade of experience with implanting drug-eluting stents, (DES), the best treatment for restenosis on these devices remains unknown. The drug-eluting balloons are a promising alternative which avoid the possibility of a new layer of metal on the restenotic injury. This study compared the performance of these balls...

Previous studies of non-inferiority (SORT-OUT III and V) compared the biodegradable polymer biolimus-eluting stent (BES) with permanent polymer stent and sirolimus-eluting stent (SES) or everolimus-eluting stent (EES), showing no differences, although the data is still contradictory. The aim of this study was to evaluate whether the recently approved BES is not inferior to EES in...

There is still concern about the safety of drug-eluting stents (DES) due to the possibility of late and very late thrombosis. Dual antiplatelet aggregation for a year is recommended for patients receiving DES. The objective of this study was to test the non-inferiority of a new drug-eluting stent in terms of endothelial coverage after 3...

From the total of 1900 patients in the FREEDOM study, 1248 did not require insulin (631 received angioplasty and 617 received CABG) and 602 if required (325 received angioplasty and 277 received CABG). Insulin dependent patients were more obese, with higher glycosylated hemoglobin, increased incidence of heart failure and increased incidence of acute coronary syndromes....